2026 Poster Presentations

POSTER AWARD WINNERS WILL BE ANNOUNCED WEDNESDAY AT 10:45AM AND THURSDAY AT 1:30PM

Poster Session A: Tuesday - Wednesday (morning)

A01: Design of a Deimmunized EndoS for IgG-Mediated Diseases Using the ADAx Platform, Presented by Angeline T., ADAXION Therapeutics

A02: Accurate mAb Sizing by CE-SDS Using the NIST mAb as a Ladder for the Agilent ProteoAnalyzer System, Presented by Kyle L., Agilent Technologies

A03: Advanced Antibody Discovery Platforms for Accelerated Development of Next-Generation Biologic Therapeutics, Presented by Omer K., AlivaMab Biologics

A04: Optimizing Membrane Protein Peptide Mapping via RapiGest SF-Assisted Multi- Protease Digestion and Microwave Assisted Acid Hydrolysis, Presented by Tian T., Amgen, Inc.

A05: Optimizing Rapid, High-Throughput Accelerated Stability Profiling of IgG and VHH-Fc, Presented by Chacko C., AstraZeneca

A06: Accelerating Developability for Biologics: Automating Assays and Data Upload, Presented by Mark H., AstraZeneca

A07: Challenging Proteins – The Matrix Approach for Soluble Expression, Presented by Vandna K. & Cerrone C., Bayer CropScience

A08: A Next-Generation Workflow for Safe TCR Mimic Antibody Discovery: The ValidaTe™ Platform, Presented by Jörg B., BioCopyAG

A09: Superior Multicolor Spectral Panels Using StarBright UltraViolet, Violet, Blue, Yellow, and Red Dyes, Presented by Anjilna W., Bio-Rad Laboratories

A10: Rapid Lead Generation with the Pioneer Antibody Discovery Platform, Presented by Anjilna W., Bio-Rad Laboratories

A11: 3dpredict/Ab - High Throughput Antibody Structure and Ensemble Protein Property Predictions, Presented by Alain A., Chemical Computing Group

A12: Predictive Modeling of Antibody Stability Using Molecular Descriptors and Long-Term Data on Acidic Charge Variants, Presented by Shu M., Daiichi Sankyo Co., Ltd.

A13: A PILRA Antagonist Antibody Blocks Ligand Binding and Recapitulates the Protective Loss-of-Function Phenotype Associated with Reduced Alzheimer’s Disease Risk, Presented by Taggra-Nicole J., Denali Therapeutics

A14: Multiple Approaches for Antigen Production and Purification, Presented by Miguel M., FairJourney Biologics

A15: Long Loops Under the Lens: Interrogating the Developability of Antibodies with Extended CDR-H3 Regions, Presented by Marcel P., Ghent University

A16: Ginkgo's High-Yield Protein Expression Tools: Cell Free Protein Synthesis Kits and Methanol-Free Pichia pastoris, Presented by Cynthia C. & Monica M., Ginkgo Bioworks

A17: Rapid Process Development in Cell Line Optimization Utilizing GORE Protein Capture Device with Protein A, Presented by Jeffrey C., W.L. Gore & Associates, Inc.

A18: Development of IMC-S118AI ImmTAAI, TCR Targeted PD-1 Agonist Bispecific for the Treatment of Type I Diabetes, Presented by Miriam H., Immunocore Limited

A19: Building Better Purifications: Automation-Enabled Optimization Across Chromatography Workflows, Presented by Anusha C., Integrated Micro-Chromatography Systems, Inc. (IMCS)

A20: Harnessing Fungal Hosts for Recombinant Lipase Production, Presented by Lixuan H., International Flavor and Fragrances, Inc.

A21: "Stapling" scFv for Multispecific Biotherapeutics of Superior Properties, Presented by Jinquan L., Johnson & Johnson Innovative Medicine

A22: Development of a Versatile Microbial Platform for Rapid Production and Purification of VHH Antibodies, Presented by Olivier J., Kaneka Eurogentec

A23: GMP VHH Platform for Rapid Tox and Clinical Access, Presented by Celine R., Kaneka Eurogentec

A24: Small-Scale Workflow Formats Allow for Increased Throughput to Meet Growing Demand in a Protein Biochemistry Laboratory, Presented by Cameron M., Kite Pharma, A Gilead Company

A25: Massively Parallel Screening of TLR-Targeting Peptides for Dry Age-Related Macular Degeneration, Presented by Moon-Hyeong S., Korea Institute of Science and Technology

A26: Kuhner TOM for Off-Gas Analysis in Shake Flasks, Presented by Michael K., Kuhner Shaker

A27: Design and Production of Antibody Fragments for Lateral-Flow Immunoassays, Presented by Yoichi K., Kyoto Institute of Technology

A28: Accelerating AI-Guided Antibody and Protein Discovery via Lab-in-the-Loop Expression with ALiCE® HTPE, Presented by Jonathan F., LenioBio GmbH

A29: Standardisation vs Customisation: The Power of a Combined Approach for High Quality Target Protein Generation, Presented by Beth W., LifeArc

A30: Improving Protein Stability Through Deep Learning Method: The AIACCLBIO® Platform, Presented by Li H., Matwings Technology

A31: Whole-Genome CRISPR Screens Elucidate Genetic Means of Reducing Lactate and Ammonia in CHO Bioprocessing, Presented by Corey K., MilliporeSigma

A32: Innovative Function-Based Screening Platform Accelerating T-Cell Engager Discovery, Presented by Musheng B., Nona Biosciences

A33: De Novo Fully Human VH Antibody Discovery Enabled by Nona Bioscience’s Hu-mAtrIx™ AI Model, Presented by Imran C., Nona Biosciences

A34: Comparative Assessment of Protein Expression Platforms, Presented by Lindsey E., Novartis

A35: Functional Membrane Proteins - Ready in 48 Hours, Presented by Aujan M., Nuclera

A36: Cell-Free–Produced Antibodies Match CHO for Binding Assessment, Presented by Yvonne T., Nuclera

A37: A New Layer of Developability Screenings with the PAIA Microplate Technology: The pH-Dependent FcRn Binding and Release Assay, Presented by Sebastian G., PAIA Biotech GmbH

A38: Usage of Promega’s Viability PCR Reagent in Gene Therapy Applications, Presented by Steven E., Promega Corporation

A39: Streamlined Protein Production Using a Flexible Toolbox, Presented by Thilo K., Richter BioLogics GmbH

A40: Use of Expi293™ PRO Transient System for Protein Production: LMR Evaluation, Presented by Farhan L., Sanofi

A41: Deep Mining the Antibody Repertoire from LILRB1/2 Immunizations Using Bulk RNA NGS, Presented by Nanna B., Servier-Symphogen

A42: Engineered Peptide Shuttle for BBB Penetration: A Modular Delivery Platform for Glioblastoma Therapeutics, Presented by Mi Young L., Soonchunhyang University

A43: Multimodal Deep Learning Integration of Genomic, Imaging, and Proteomic Data for Enhanced Disease Risk Prediction, Presented by Wonil C., Soongsil University

A44: High-Throughput Antibody and Mini-Protein Screening on SPOC SPR Chips for Lead Identification and Optimization, Presented by Lydia G., SPOC Biosciences

A45: High-Throughput Wet-Lab Validation and Rich SPR Data Generation for Reinforcement Learning (RL) and Supervised Fine-Tuning (SFT) of AI Models, Presented by Engin Y., SPOC Biosciences

A46: Integrating Early Consumer Feedback in the Concept Development of Seaweed-Based Supplements, Presented by Hazel K., Stanford University

A47: Automated CDR Redesign of Anti–PD-L1 Antibodies Using the Ab-ARS™, Presented by Namita D., Syntekabio USA

A48: Moving Science Across the Country: Launching Structural Biology at Takeda Boston, Presented by Maria H., Takeda Pharmaceuticals

A49: Identification of Antigen-Specific Single-Domain Antibodies Using Integrated In Vivo and In Vitro Approaches, Presented by Olivia E. & Anushree B., Takeda Pharmaceuticals

A50: Affinity Capture Purification Solutions for Novel Antibody Modalities, Presented by Cole D., Thermo Fisher Scientific

A51: Reduce Manufacturing Cost of Antibody-Based Therapeutics with an Alternative-Source Protein A Resin, Presented by Summer S., Thermo Fisher Scientific

A52: New Mid-Scale Workflows for 20mL - 50mL in Automation Friendly Format, Presented by Sam E., Thomson Instrument Company

A53: Characterizing Nanoparticles by Transmission Electron Microscopy, Presented by Guillaume C., University of California, San Diego

A54: High Diversity Gene Libraries Facilitate Machine Learning-Guided Exploration of Fluorescent Protein Sequence Space, Presented by Anissa B., University of Oregon, Eugene

A55: Antibody Fragments for Reversal of Fentanyl Overdose: Structure-Guided Design, Affinity Maturation, and scFv In Vivo Validation, Presented by Dustin H., University of Washington

A56: Cost-Effective and Customizable Production of Pharmaceutical Proteins in the Fungal Factory Trichoderma reesei, Presented by Pedro G., VTT - Technical Research Centre of Finland

A57: Bispecific Antibody Discovery: From Strategic Design to Fit-for-Purpose Screening & Characterization, Presented by James S., WuXi Biologics

Poster Session B: Wednesday (afternoon) - Thursday

B01: Automated Multi-Step Purifications for Challenging Proteins Using a Modified ÄKTA Pure FPLC System, Presented by Andrew G., Aera Therapeutics

B02: Corynex® Microbial Expression Platform for Sustainable Production of Long-Chain Peptides like GLP-1–Related Peptides, Presented by Hayato N., Ajinomoto Co., Inc.

B03: Mapping Antibody Behaviour: Multi-Dimensional Data for Developability, Presented by Alec T., Apoha

B04: Hydrodynamic Radius Maps Predict Filtration Flux of Self-Associating IgG1, Presented by Amane S., Astellas Pharma, Inc.

B05: Predicting In Vivo Tg32 Mouse Clearance Using In Vitro Non-Specific Binding Developability Assays, Presented by Jennifer D., AstraZeneca

B06: Accelerating Drug Discovery with an AI/ML-Ready Biologics Platform, Presented by Jonas K., Bayer AG

B07: Current Status and Innovations in DNA-Encoded Peptide Libraries, Presented by Yihui X., BioDuro

B08: Speed Counts While Quality Matters: A Fast-Track Approach to Bispecific Antibody Production, Presented by Eric C., Biointron

B09: Data-Driven Developability Assessment of Antibody Candidates Using High-Throughput Biophysical Assays, Presented by Gang L., Biointron

B10: Redefining Fc-Fusion Purification: Mixed-Mode Capture Followed by Strong Anion Exchange Polishing, Presented by Heidi J., Bio-Rad Laboratories

B11: Extracellular Vesicle Isolation and Analysis: Application of Anion Exchange and Size Exclusion Chromatography and Multiplex Fluorescent Western Blotting, Presented by Heidi J., Bio-Rad Laboratories

B12: Elevating Protein Purification Efficiency: Transitioning from Manual Techniques to Automated Platforms, Presented by Shadie N., Biotage

B13: High-Yield Solutions for Complex Proteins: Leveraging Expi293™ PRO for Rapid Development Empowering Faster, Scalable Protein Expression for Complex Biologics, Presented by Mariko R., Bristol Myers Squibb

B14: Optimizing Transient Expression in CHO-K1 Cells with PEI: A Scalable and Cost-Effective Approach for High-Yield Protein Production, Presented by Xiaoli L., Cellplus Bio

B15: Harnessing the DoppeLib™ Technology to Transform Multispecific and Biparatopic Antibody Discovery, Presented by Kohei K., Chiome Bioscience, Inc.

B16: A New Era for Full-Length Membrane Targets: From Lysate to Structure- and Assay-Ready Protein in 45 Minutes, Presented by Barbara M., Cube Biotech GmbH

B17: High-Performance Antibody Discovery Using DPBIO CytoSpark Microfluidic Droplet Sorting System, Presented by Jennifer S., Dapu Biotechnology Co., Ltd. (DPBIO)

B18: Comparative Analysis of Harbor-IN Transposases mRNA or Protein Activity in T Cells by Digital PCR, Presented by Cintia G., Demeetra

B19: Next-Generation Cryo-EM for Antibodies, Targets, and Small Molecules: Accelerating Discovery Through High-Resolution Structural Biology, Presented by Christopher A., FairJourney Biologics

B20: The Evolution of Antibody Screening: Automation-Integrated BLI for Next-Generation Discovery Workflows, Presented by Hongshan L. & Qi X., Gator Bio

B21: A Guided Design Framework for the Optimization of Therapeutic-Like Antibodies, Presented by Amy W., Genentech

B22: High-Throughput Secondary Purification Workflow for Complex Therapeutic Formats at Small Scale, Presented by Ingrid K., Genentech

B23: Improving Scalable, High-Throughput Affinity Protein Purification Workflows with Magnetic Beads-Based Automated Solutions, Presented by Luciana R., GenScript USA, Inc.

B24: The Virtuous Cycle: Integrating an Industrial-Scale Biophysical Data Engine (PROPHET-Ab) with Guided Generative AI for High Performance Datasets, Presented by Ammar A. & Josh M., Ginkgo Bioworks

B25: Extended Cycling Durability, High Productivity Affinity Purification Using Gore Protein A Affinity Membranes, Presented by Jonny J., W.L. Gore & Associates, Inc.

B26: Toxoplasma gondii GRA2-Derived Peptides Mediated Apoptosis and Immune Clearance Overcome Drug Resistance via IFT22 Signaling in Lung Cancer, Presented by Chul-Su Y., Hanyang University

B27: Differentiation of Protein Aggregates and Silicone Oil Droplets Using Three-Dimensional Homodyne Light Detection (3D-HLD), Presented by Kentaro O., Hitachi High-Tech Corporation

B28: New Method for Rapid Antibody Purification for Top-Down MS with Low / No Aggregation, Presented by Jane J., i3 Membrane Corporation

B29: Multimodal Fusion of Empirical Structural Data and Deep Learning for Improved Modeling of Antibody–Antigen Complexes, Presented by Faraz C., Immuto Scientific, Inc.

B30: Advancing Nativeness Assessment of Nanobodies and Paired Human Antibodies with AbNatiV2, Presented by Aubin R., Imperial College London

B31: H5N1 Pandemic Preparedness: Building a Comprehensive Immunological Toolbox, Presented by Patrick R., IQVIA Laboratories

B32: Transforming Tumor Research: Engineering MHCs as Versatile Reagents, Presented by Maggie G., KACTUS

B33: GPCR VLPs & Nanodiscs for Drug Discovery, Presented by ManHee S., KACTUS

B34: Development of Clec9A-Targeting Protein Nano-Vaccines for Dendritic Cell-Based Cancer Immunotherapy, Presented by Seongjoon K., Kangwon National University

B35: Stepwise Engineering of Bioactive Peptides for Dual-Functionalized Oncolytic Nanoparticles for Tumor Specific Apoptosis, Presented by Cheol-Ki ., Kangwon National University

B36: Strategy and Workflow for High Concentration Protein Formulation Development at KBI Biopharma, Presented by Richard J., KBI Biopharma

B37: Machine-Learning Assisted Long-Term Stability Prediction of Biologics Based on T0 Molecular Descriptors, Presented by Ruomeng Q., Merck & Co., Inc.

B38: Functional Screening of AI-Designed Peptide Libraries Identifies Novel Opioid GPCR Agonists, Presented by Simon B., Orbit Discovery

B39: Extensive Developability Profiling of a Diverse mAb Panel – From Biophysical Insight to PK Prediction, Presented by Aris P., PAIA Biotech GmbH

B40: High-Titer Recombinant Peptide Productionvia P. fluorescens Fusion Partners, Presented by Yinghui L., Primrose Bio

B41: Overcoming ncAA Production Bottlenecks: High-Titer Antibody Expression with 100% pAzF Incorporation at Scale and Minimal Host Toxicity, Presented by Jasmina R., Primrose Bio

B42: A Staged Predictive Formulation Analytics Framework from Early Screening to High-Concentration Drug Product Stability, Presented by Richard P., ProJect Pharmaceutics

B43: Towards a Non-Chromatographic One-Pot Purification of Recombinant Antibodies in Plants, Presented by Julia S., Queensland University of Technology

B44: ML-Empowered Platform for Optimal Pairing of Monospecific Arms into Bispecific Constructs Using Structural Descriptors, Presented by Jonathan D., Servier-Symphogen

B45: Nano-Flow Cytometry Enables to Evaluate the Nano Size SARS-CoV-2 Spike Protein Aggregate and Reveal the Mechanism, Presented by Yuya H., Shionogi & Co., Ltd.

B46: The Bacterial IdeS Protease as a Strategy for Tumor Regression, Presented by Mark C., Tavotek Biotherapeutics

B47: Expi293™ PRO Expression System: Expression Improvements Across Different Classes of Proteins, Product Quality Assessment and Automated Purification, Presented by Alex K., Thermo Fisher Scientific

B48: Enhancing CHO Cell Productivity: Impact of Animal-Origin-Free Peptone Supplementation in Fed-Batch and Intensified Fed-Batch Processes, Presented by Ashwin G., Thermo Fisher Scientific

B49: Automating the Expi293™ PRO Expression System for mAb and Fc Fusion Protein Production, Presented by Matt M., Thermo Fisher Scientific

B50: Expi293™ PRO Expression System: A Next-Generation Expression System for Higher Yields Across a Wider Variety of Proteins, Presented by Chao Yan L., Thermo Fisher Scientific

B51: Universal Rapid Clear® 24-Well Filter Plate (7mL); A 5-Minute Spin for Clarification Solution for all Molecule Types, Presented by Alberto E., Thomson Instrument Company

B52: Cuvette-Based Spectroscopic Technology for the Formulation and Stabilization of Biologics, Presented by Sylvia A., Tulane University

B53: High Throughput Characterization of Biologics and Their Stability via Cuvette Based Dialysis and Automatic Continuous Dilution, Presented by Curt J., Tulane University

B54: Semaglutide Production by Semi-Recombinant Method with Escherichia coli, Presented by Sung-Gun K., U1 University

B55: Monitoring of High-Risk HCPs Using an Optimized SWATH-MS Library: Impacts of Cell-Line Differences and Protein A Purification, Presented by Tomoko M., University of Osaka

B56: Pioneering TCR Optimization via Targeted Engineering & HTP Screening, Presented by Guangbo L., WuXi Biologics

B57: Simplifying Multigene Vector Design and Construction for Streamlined Development of Complex Therapeutics, Presented by Aaron C., Zymo Research Corporation